Balancing innovation and Common Sense In Oncology (CSO)

Common Sense in Oncology – Why

Integration of evidence-informed decision making into policymaking

Finding Grants and writing a good grant proposal

Biostatistics for clinician researchers 1: Types of data

Biostatistics for clinician researchers 2: Survival and K-M analysis

KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer

Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients

Adjuvant radiotherapy has no benefit following radical prostatectomy

Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC

Myeloma treatment and prognosis